NLC-Based Delivery Strategies: A Practical Guide for Scientists and Product Teams

Compared to traditional lipid-based systems, nanostructured lipid carriers (NLCs) are transforming modern drug delivery by offering higher drug loading, improved stability, and controlled drug release. As innovative carriers, NLCs have been widely applied in pharmaceuticals, cosmetics, and nutraceuticals. At Creative Biolabs, we support scientists and innovators with advanced formulation design, modular targeting systems, and comprehensive analytical services to accelerate development from concept to application. This article explores how NLCs work, why they matter, and how they are reshaping the future of targeted delivery.

Introduction: What Are Nanostructured Lipid Carriers (NLCs)?

Nanostructured lipid carriers are second-generation lipid nanoparticles that mix solid lipids with a small fraction of liquid lipids. This "imperfect" internal matrix creates extra space for drug molecules. Therefore, NLCs reduce drug expulsion during storage, raise loading capacity, and enable controlled release compared with early lipid carriers such as solid lipid nanoparticles (SLNs). Moreover, because the materials are lipidic, NLCs are typically biocompatible and well-suited for oral, dermal, ocular, pulmonary, and parenteral administration routes.

Core features of NLCs include:

• High encapsulation for small molecules, peptides, and some biologics
• Stability against crystallization-driven drug expulsion
• Custom release (immediate, sustained, or triggered)
• Scalable compositions using pharmaceutically accepted lipids and surfactants

Plain-English snapshot:

Think of NLCs as a roomier, more stable lipid suitcase. The mixed-lipid inside gives your cargo (the drug) more places to fit, so it stays packed and releases at the pace you design.

Nanostructured lipid carriers are classified into three types based on lipid composition and formulation (Figure 1). Each type leverages structural advantages to optimize chemotherapeutic delivery efficiency and stability.

• Imperfect NLCs mix lipids with varied fatty acid chains, creating crystal lattice imperfections to boost lipophilic drug loading.
• Amorphous NLCs combine solid and liquid lipids to form a non-crystalline matrix, minimizing drug expulsion during storage.
• Multiple NLCs (oil-in-fat-in-water) feature a solid lipid matrix enclosing liquid oil nano-compartments, enhancing drug solubility and enabling controlled release.

Fig.1 Different types of NLCs.¹

How Do NLCs Work in Targeted Drug Delivery?

Nanostructured lipid carriers (NLCs) enhance targeted drug delivery by combining biological compatibility with flexible surface design and optimized pharmacokinetics. Their mechanism begins at the lipid matrix level, which allows for high drug loading and controlled release. The lipid matrix of NLCs is composed of a mixture of solid and liquid lipids. Drug molecules are either molecularly dispersed or solubilized within this matrix, thus reducing premature degradation and extending systemic circulation. In targeted delivery, two layers of strategy are typically applied:

Passive targeting

Passive targeting is primarily achieved through particle size control (typically 50-200 nm) and surface charge. These features allow NLCs to exploit the enhanced permeability and retention (EPR) effect in tumors or inflamed tissues, leading to natural accumulation at disease sites. Moreover, their lipidic composition can promote lymphatic uptake and bypass first-pass metabolism.

Active targeting

Active targeting further improves precision by modifying the NLC surface with biological ligands. Antibodies, peptides, aptamers, folic acid, or carbohydrates can be conjugated to the nanoparticle surface for specific targeting to tumors, inflamed tissues, or the central nervous system. The surface modification of NLCs increases intracellular uptake via receptor-mediated endocytosis and minimizes off-target exposure.

Sustained drug release

Once internalized, NLCs can release their therapeutic payload gradually via lipid matrix erosion or diffusion mechanisms. In addition, integration of surface PEGylation or hydrophilic coatings can further protect NLCs from opsonization and phagocytic clearance, thus prolonging circulation time. Their structure also allows co-delivery of multiple agents, such as chemotherapeutics and siRNA, to support combination therapies.

Tip for teams

Start with your clinical or product goal, back-solve to the desired PK/PD, then tune lipid composition, particle size, and ligand chemistry to hit that target profile.

At Creative Biolabs, you can pair NLCs with our Module Delivery Systems to mix-and-match modules: lipid cores, stealth coatings, linkers, and ligands. This modularity helps your team iterate faster, validate MoA-relevant targeting, and shorten time to lead formulation.

Advantages of NLCs Over Other Nanoparticle Systems

Nanostructured lipid carriers (NLCs) offer significant advantages compared to conventional lipid-based systems such as liposomes and solid lipid nanoparticles (SLNs), as well as polymeric nanoparticles.

Higher Drug Loading Capacity

• The mix of solid and liquid lipids creates an "imperfect" matrix, providing more room for drug molecules.
• This allows NLCs to achieve 80-95% encapsulation efficiency, much higher than SLNs or liposomes.

Reduced Drug Expulsion During Storage

• SLNs tend to crystallize over time, pushing out the drug.
• NLCs disrupt crystallinity using liquid lipids, preventing drug leakage during long-term storage.

Improved Stability Compared to SLNs and Liposomes

• NLCs resist polymorphic transitions, aggregation, and degradation better than first-generation lipid carriers.
• They remain stable in aqueous suspension without rapid phase separation.

Controlled and Sustained Drug Release

• Their lipid matrix enables tailored release profiles (immediate, sustained, or delayed) depending on formulation.
• This helps reduce dosing frequency and peak-related toxicity.

Enhanced Bioavailability of Poorly Soluble Drugs

• NLCs improve the solubility and permeability of lipophilic drugs by encapsulating them in a lipid-based core.
• This is especially useful in oral, dermal, and nasal delivery routes.

Biocompatibility and Lower Toxicity

• They are made of GRAS (Generally Recognized as Safe) lipids.
• Unlike polymeric or metallic nanoparticles, which may cause cytotoxicity or immunogenicity, NCLs are less likely to trigger cytotoxicity.

Capability for Passive and Active Targeting

• Naturally sized in the 50-300 nm range, they can passively accumulate in tumors (EPR effect).
• Surface modification with ligands enables active targeting.

Scalable and Industry-Friendly Manufacturing

• NLCs can be produced using high-pressure homogenization, microemulsion, or solvent-free methods, which are scalable to industrial levels.
• Lower reliance on toxic organic solvents makes them regulatory-friendly.

Versatility Across Drug Types and Delivery Routes

• Suitable for oral, parenteral, nasal, ocular, pulmonary, dermal, and gene delivery applications.
• Be able to encapsulate small molecules, peptides, antioxidants, antibiotics, and even genetic material.

Industrial Applications and Therapeutic Fields for NLCs

Nanostructured lipid carriers (NLCs) are widely used across pharmaceuticals, cosmetics, nutraceuticals, and emerging biomedical applications due to their versatility, safety, and enhanced drug delivery capabilities. Their ability to encapsulate both hydrophilic and hydrophobic molecules while improving solubility, stability, and bioavailability makes them a superior choice

for being applied in many industrial and biomedical contexts.

Oncology:

In cancer treatment, NLCs are employed to improve the solubility, bioavailability, and targeted delivery of chemotherapeutic agents such as paclitaxel, doxorubicin, and curcumin. These systems enhance drug accumulation in tumor tissues through passive targeting (EPR effect) and can be further engineered with ligands for active targeting.

CNS:

NLCs are used in the treatment of neurological disorders. They can deliver therapeutic agents for diseases such as Alzheimer's and Parkinson's diseases, as their lipid nature facilitates passage across the blood-brain barrier.

Anti-infectives:

Anti-infective applications of NLCs include encapsulation of antibiotics and antiviral agents. They can improve drug penetration into infected tissues and reduce antimicrobial resistance risks.

Cosmeceuticals & Dermatology

In cosmetics, NLCs enhance skin hydration, increase active ingredient retention, and improve stability of sensitive compounds such as vitamins and antioxidants. Currently, they are used in the formulation of anti-aging creams, sunscreens, wound healing formulations, and acne treatments for improved effects.

Nutraceuticals & Functional Foods

Bioactive ingredients:

NLCs are increasingly used to encapsulate bioactive food ingredients such as omega-3 fatty acids, coenzyme Q10, curcumin, and fat-soluble vitamins. As carriers for these bioactive ingredients, they can protect them from oxidation, improve the intestinal absorption, and support the sustained release in gastrointestinal tract delivery systems.

Taste-masking & shelf-life:

Lipid matrices can help mask bitterness and extend stability.

Emerging Applications: Gene Delivery and Vaccines

Recent studies show NLCs can be engineered to deliver nucleic acids such as siRNA, mRNA, and DNA for gene therapy and vaccination. Their biocompatibility and ability to bypass enzymatic degradation make them strong candidates as non-viral gene vectors. Additionally, NLCs are investigated for mucosal vaccine delivery (nasal, oral, pulmonary), enhancing immune responses without needles.

Why teams choose NLCs:

NLCs can provide broad formulation flexibility across sectors while maintaining consumer-friendly, lipid-based compositions.

Practical Playbook: Building an NLC-Based Delivery Strategy

Designing an effective NLC-based delivery system requires more than selecting lipids. This section offers a step-by-step roadmap that guides researchers from target definition to scalable production, helping them avoid common pitfalls in the development toward clinical or commercial use.

1) Define the Target Product Profile (TPP)

• Indication & route: IV, oral, dermal, ocular, pulmonary, or intranasal
• PK/PD goals: Onset, C_max smoothing, half-life, and local vs. systemic exposure
• Release profile: Immediate, sustained, or environment-triggered releases
• Dose: Daily vs. weekly

2) Choose Lipid System & Surfactant

• Solid lipids: Glyceryl behenate, stearic/palmitic derivatives
• Liquid lipids: Medium-chain triglycerides, oleic derivatives
• Surfactants: Polysorbates, poloxamers; consider PEGylation logic
• Target 80-200 nm, PDI ≤ 0.25, and zeta for stability

3) Add Targeting & Stealth Modules

• Passive: Size/charge optimization and surface hydration/PEG
• Active: Ligands (antibody, peptide, aptamer, carbohydrate) via stable linkers

Use Creative Biolabs' Module Delivery Systems to mix cores, coatings, and ligands quickly.

4) Formulate & Process

• Methods: High-pressure homogenization, microfluidics, or ultrasonication
• DoE to tune lipid ratios, surfactant levels, and cycles/pressure
• Control temperature to preserve APIs and avoid lipid polymorph shifts

5) Characterize & Qualify

• Size/PDI, zeta potential
• Encapsulation efficiency & loading
• In-vitro release (dialysis/sink methods)
• Stability (stress, accelerated, long-term)
• Ligand density and binding assays (if targeted)

6) Translate & Scale

• Pilot batches with inline particle analytics
• Robust SOPs and material traceability for GxP
• Regulatory-friendly CMC packages and risk registers

Pro move: Lock down a single source of truth for composition, process windows, and QC acceptance ranges. This accelerates tech transfer and review.

Compliance, Quality, and Risk Controls

• Excipient selection: Use compendial-grade lipids/surfactants with clear CoAs.
• Impurities: Track peroxide values and free fatty acids that may grow during storage.
• Container/closure: Match packaging to oxygen/light sensitivity.
• Analytics: Validate repeatability for size/PDI and loading; implement orthogonal methods for release/identity.
• Stability: Include thermal cycling to stress crystallization and mitigate drug expulsion risks.

Challenges in Development and Clinical Translation of NLCs

While NLCs are powerful, teams must plan for:

• Scale-up and cost: The CAPEX/OPEX and reproducibility of NLC scale-up production can be impacted by the equipment choice (e.g., high-pressure vs. microfluidics).
• Regulatory path: Lipid excipients are familiar, yet NLC-specific guidance is still evolving. Early dialogue helps.
• Long-term safety: Chronic exposure datasets are growing, but need thoughtful study design and surrogate endpoints.
• Supply chain robustness: Consistent lipid/surfactant quality and traceability are essential for GxP readiness.

How Creative Biolabs de-risks your program

• Module-first design to speed early selection and reduce reformulation cycles
• QC/analytical panels (size/PDI, zeta, loading, release, stability, ligand density) aligned to target claims.
• Scalable process maps from bench to pilot, with DoE to lock critical parameters
• Cross-functional documentation to support regulatory submissions

Related Services You May Be Interested in

FAQs

Conclusion

NLCs give teams a flexible, biocompatible, and scalable path to improve loading, stability, targeting, and release across pharma, dermal, and nutraceutical products. With clear goals, modular design, and the right analytics, you can progress from concept to clinical-ready far more efficiently.

Ready to move? Partner with Creative Biolabs to:

• Rapidly prototype NLC cores, stealth coats, and ligands with our Module Delivery Systems
• Lock process windows via DoE and build regulatory-friendly CMC
• Scale with robust QC and documentation that accelerates review

Call to action:

Tell us your target, route, and PK/PD goals—we'll design an NLC strategy, prepare a development plan, and provide a fast quote.

References

1. Haider, M., Abdin, S. M., Kamal, L. & Orive, G. "Nanostructured Lipid Carriers for Delivery of Chemotherapeutics: A Review." Pharmaceutics 12, 288 (2020). https://www.mdpi.com/1999-4923/12/3/288. Distributed under Open Access license CC BY 4.0, without modification.
2. Khan, S., Sharma, A. & Jain, V. "An Overview of Nanostructured Lipid Carriers and its Application in Drug Delivery through Different Routes." Adv Pharm Bull 13, 446–460 (2023). https://apb.tbzmed.ac.ir/Article/apb-34577.
3. Chauhan, I., Yasir, M., Verma, M. & Singh, A. P. "Nanostructured Lipid Carriers: A Groundbreaking Approach for Transdermal Drug Delivery." Adv Pharm Bull 10, 150–165 (2020). https://apb.tbzmed.ac.ir/Article/apb-27690.